HHV-8 B Inhibitors

HHV-8 B inhibitors, also known as Human Herpesvirus 8 B inhibitors, constitute a class of chemical compounds specifically designed to target and disrupt the replication cycle of Human Herpesvirus 8 (HHV-8). HHV-8, also known as Kaposi's sarcoma-associated herpesvirus (KSHV), is a member of the herpesvirus family and is associated with several malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. HHV-8 B inhibitors are developed with the primary objective of interfering with various stages of the HHV-8 viral lifecycle, thereby impeding its ability to infect host cells and propagate within the human body.

The mechanisms of action of HHV-8 B inhibitors are diverse, reflecting the multifaceted nature of the HHV-8 replication cycle. These inhibitors may target various viral enzymes and processes critical for viral replication, such as viral DNA polymerase or viral RNA polymerase. Some HHV-8 B inhibitors function as nucleoside analogs, disrupting the synthesis of viral DNA or RNA by being incorporated into the growing nucleic acid chain and causing premature termination. Others may interfere with the activity of viral proteases, essential for the cleavage of viral polyproteins into functional components required for viral assembly. Additionally, inhibitors within this class may inhibit viral protein kinases or terminase complexes, crucial for viral maturation and DNA packaging. By hampering these key steps in the HHV-8 replication cycle, HHV-8 B inhibitors represent a vital tool in the study of HHV-8 biology and hold promise for potential future applications beyond their current research-focused role.